NO20063221L - Fremgangsmate for behandling av matinntak - Google Patents

Fremgangsmate for behandling av matinntak

Info

Publication number
NO20063221L
NO20063221L NO20063221A NO20063221A NO20063221L NO 20063221 L NO20063221 L NO 20063221L NO 20063221 A NO20063221 A NO 20063221A NO 20063221 A NO20063221 A NO 20063221A NO 20063221 L NO20063221 L NO 20063221L
Authority
NO
Norway
Prior art keywords
person
food intake
eating
procedure
obesity
Prior art date
Application number
NO20063221A
Other languages
English (en)
Norwegian (no)
Inventor
Nir Barak
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of NO20063221L publication Critical patent/NO20063221L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20063221A 2004-04-22 2006-07-11 Fremgangsmate for behandling av matinntak NO20063221L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (1)

Publication Number Publication Date
NO20063221L true NO20063221L (no) 2006-10-06

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063221A NO20063221L (no) 2004-04-22 2006-07-11 Fremgangsmate for behandling av matinntak

Country Status (10)

Country Link
US (5) US7737165B2 (https=)
EP (1) EP1737454A4 (https=)
JP (1) JP2007533733A (https=)
KR (1) KR20060134041A (https=)
BR (1) BRPI0506807A (https=)
CA (1) CA2553309A1 (https=)
EA (1) EA200601414A1 (https=)
IL (1) IL176793A0 (https=)
NO (1) NO20063221L (https=)
WO (1) WO2005101979A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
UA98938C2 (ru) * 2006-06-16 2012-07-10 Теракос, Инк. Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP5513378B2 (ja) * 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
KR101621726B1 (ko) 2008-05-27 2016-05-17 더 유니버시티 오브 멜버른 유스타키오관 기능장애 치료용 국소 약학적 조성물
US20120115778A1 (en) * 2009-07-15 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
JP2013507713A (ja) * 2009-10-13 2013-03-04 ネステク ソシエテ アノニム 食物摂取を評定するシステム及びそのシステムを使用する方法
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
US8778960B2 (en) * 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
ES2969301T3 (es) * 2017-02-02 2024-05-17 Otolanum Ag Composición intranasal que comprende betahistina
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20250154480A (ko) * 2023-02-28 2025-10-28 바이오하벤 테라퓨틱스 리미티드 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) * 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69939027D1 (de) * 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2002087556A2 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
AU2003266165A1 (en) 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline

Also Published As

Publication number Publication date
US20080004322A1 (en) 2008-01-03
WO2005101979A3 (en) 2006-07-27
WO2005101979A2 (en) 2005-11-03
EP1737454A2 (en) 2007-01-03
US20060073217A1 (en) 2006-04-06
CA2553309A1 (en) 2005-11-03
US7737165B2 (en) 2010-06-15
US20080004324A1 (en) 2008-01-03
EP1737454A4 (en) 2007-08-08
US20060084686A1 (en) 2006-04-20
IL176793A0 (en) 2006-10-31
BRPI0506807A (pt) 2007-05-29
JP2007533733A (ja) 2007-11-22
US20080051439A1 (en) 2008-02-28
KR20060134041A (ko) 2006-12-27
EA200601414A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
NO20063221L (no) Fremgangsmate for behandling av matinntak
WO2006105345A3 (en) Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
WO2004110385A3 (en) Modulators of the glucocorticoid receptor and method
WO2006129193A3 (en) Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
TW200833336A (en) Method of treatment of obesity
WO2006091505A3 (en) Neuropeptide y receptor agonists
Henkin et al. Effective treatment of smell loss with theophylline
Varma et al. Coffee (Caffeine) inhibits Cataract Formation in Humans
Guydish et al. Predictors of retention among drug users in day treatment
Reimer et al. Using a diet and drug combination treatment prior to pregnancy to improve maternal health in rats
Aguirre‐Fuerte et al. ALTERATIONS IN THE ENDOCANNABINOID SYSTEM IN ASTROCYTES RELATED TO COMMERCIAL SWEETENER INTAKE
Silpanisong et al. Chronic Hypoxia Alters the Response of Fetal Ovine Middle Cerebral Arteries to Endothelin‐1 (ET‐1)
Salmean et al. The uremic molecule p‐cresol is lowered after supplementing the diet of chronic kidney disease patients with fiber
McEniery et al. Mechanisms Underlying Obesity‐Related Hypertension: An Experimental Weight Gain Study in Humans
Wilson et al. Muscle Protein Synthesis Refractoriness is overcome by an Oral Leucine or Carbohydrate Supplement
Dudley Domestic Partner Proposals
Schweikert Covariate Adjusted Confidence Intervals for the Incremental Cost-Effectiveness Ratio in Non Randomized Trails, Comparing Fieller and Bootstrap Methods-An Example from the Sarah Study
MILANI et al. ORAL: ASSESSING THE RELATIONSHIP BETWEEN FOOD INSECURITY & WEIGHT STATUS OF THE ELDERLY APPLYING FACPS-FSSM MEASUREMENT TOOL, ADOPTED FOR IRANIAN ELDERLY
Kim et al. The trend of Korean staple food intake and prevalence of obesity in Korean adults: The Korean national health and nutrition examination survey (KNHANES) 1998–2012
Zheng et al. Enhanced muscle contractility and anti‐fatigue proprieties of CordyMax5
Fu et al. Neither gender nor the menstrual cycle affects sympathetic baroreflex sensitivity during orthostasis in humans
Cui et al. ALTERED TOLL-LIKE RECEPTOR 4 ACTIVATION PLAYS A CRITICAL ROLE IN CYSTITIS PAIN: A MAPP RESEARCH NETWORK ANIMAL MODEL STUDY: PD55-02
Seifert et al. A beta 1+ 2 adrenergic receptor antagonist blunts the decrease in the cerebral metabolic ratio during exhaustive exercise in humans
Racine et al. The effect of home delivered DASH meals on the diets of older adults with cardiovascular disease
Smith et al. Effect of B‐hydoxy‐B‐Methylbutyrate (HMB) and Resistance Training on Body Composition and Functionality in Elderly Women (65–89 yrs)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application